KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Current Assets (2019 - 2025)

Historic Current Assets for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $565.5 million.

  • GoodRx Holdings' Current Assets fell 977.74% to $565.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.5 million, marking a year-over-year decrease of 977.74%. This contributed to the annual value of $659.3 million for FY2024, which is 2446.58% down from last year.
  • As of Q3 2025, GoodRx Holdings' Current Assets stood at $565.5 million, which was down 977.74% from $550.6 million recorded in Q2 2025.
  • GoodRx Holdings' Current Assets' 5-year high stood at $1.1 billion during Q1 2021, with a 5-year trough of $540.2 million in Q1 2025.
  • Over the past 5 years, GoodRx Holdings' median Current Assets value was $894.0 million (recorded in 2022), while the average stood at $848.4 million.
  • In the last 5 years, GoodRx Holdings' Current Assets soared by 1032.69% in 2023 and then plummeted by 3532.13% in 2024.
  • Over the past 5 years, GoodRx Holdings' Current Assets (Quarter) stood at $1.1 billion in 2021, then dropped by 15.53% to $919.7 million in 2022, then dropped by 5.1% to $872.8 million in 2023, then decreased by 24.47% to $659.3 million in 2024, then decreased by 14.22% to $565.5 million in 2025.
  • Its Current Assets stands at $565.5 million for Q3 2025, versus $550.6 million for Q2 2025 and $540.2 million for Q1 2025.